Physician profile
Jonathan A Eisengart
NPI 1497748495
$7,667.88
in general payments reported to CMS, 2019-2025
11 companies · $2,159 in 2025
The $2,159 reported for 2025 was more than what 89% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,620 · 2020: $71.98 · 2021: $321 · 2022: $244 · 2023: $591 · 2024: $1,660 · 2025: $2,159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,869 · Travel and Lodging: $791 · Consulting Fee: $750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,869.19 |
| Travel and Lodging | $791.24 |
| Consulting Fee | $750.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| New World Medical,INC. | $2,873.88 | 2019-2025 | Via360, Clearpath, Streamline |
| Alcon Vision LLC | $1,352.50 | 2024-2025 | Clareon, Centurion, Argos |
| Nova Eye, INC. | $1,219.21 | 2025 | |
| Sight Sciences, INC. | $470.99 | 2021-2025 | Omni Surgical System, Sion Surgical Instrument |
| Abbvie INC. | $466.64 | 2022-2025 | |
| Aerie Pharmaceuticals, INC. | $390.79 | 2019-2021 | |
| Glaukos Corporation | $274.91 | 2019-2025 | Idosetr, Idose |
| Microsurgical Technology, INC. | $269.92 | 2023 | |
| Allergan, INC. | $263.76 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $63.61 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $21.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Eisengart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.